Ceftriaxone Sodium Injection Medicine 1.0G 0.5G Antibiotic For Sepsis Treatment
| Place of Origin: | Guangdong |
|---|
Company Profile
| Location: | Hangzhou, Zhejiang, China (Mainland) |
|---|---|
| Business Type: | Manufacturer |
| Main Products: | Medicinal Tablets, Medication Capsules, Injection Medicines |
Product Detail
| Model No.: | AIA-1 |
|---|
Product Description
Ceftriaxone Sodium For Injection Medicines 1.0G 0.5G Antibiotic 1VIAL / BOX
CEFTRIAXONE SODIUM INJECTION 1.0G/0.5G
COMPOSITION:
Each vial contains:Ceftriaxone sodium (Sterile) equivalent to ceftriaxone 1.0G/0.5G.
PHARMACOLOGICAL ACTION:
Ceftriaxone is a broad-spectrum cephalosporin with a long plasma elimination half-life of approximately 8 hours in normal adults.
INDICATIONS:
Infections caused by pathogens sensitive to ceftriaxone such as
|
- |
sepsis |
|
- |
meningitis in neonates and infants |
|
- |
perioperative prophylaxis of infections |
|
- |
renal and urinary tract infections |
|
- |
respiratory tract infections, particularly pneumonia, and ear, nose and throat infections. |
|
- |
infections of the bones, joints, soft tissue, skin and of wounds. |
|
- |
abdominal infections (peritonitis, infections of the biliary tract). |
|
- |
uncomplicated gonorrhoea |
CONTRA-INDICATIONS:
Allergy to cephalosporins. In patients hypersensitive to penicillin, the possibility of allergic cross reactions
should be borne in mind.
Pregnancy and Lactation
Safety in human pregnancy has not been established. As ceftriaxone is excreted in the breast milk at low
concentrations, caution is advised in nursing mothers.
WARNINGS:
Before therapy with Oframax is instituted, careful inquiry should be made to determine whether the patient
has had previous hypersensitivity reactions to cephalosporins, penicillins or other medicines. About 10% of
penicillin- sensitive patients may also be allergic to cephalosporins although the true incidence is uncertain.
Great care should be taken if Oframax is to be given to such patients.
DOSAGE AND DIRECTIONS FOR USE:
Adults and children over twelve: 1-2g ceftriaxone once daily (every 24 hours).
In severe infections and in cases in which the pathogens are only moderately sensitive to ceftriaxone, the
daily dosage may be increased to 4 g administered daily.
Infants and young children may receive from 20-80 mg per kg body-mass daily; depending on the severity of the infection, usually 12-24 hourly.
In cases of premature babies, the daily dosage should not exceed 50 mg per kg body mass on account of the
immaturity of the infant’s enzyme systems.
SIDE EFFECTS AND SPECIAL PRECAUTIONS:
Systemic:
Gastro-intestinal complaints: Loose stools/diarrhoea, nausea, vomiting, stomatitis, glossitis.
Haematological changes: Eosinophilia, haematoma or bleeding, thrombocytopenia, neutropenia, leukopenia,
granulocytopenia and haemolytic anaemia.
Exanthema, allergic dermatitis, pruritus, urticaria, oedema, erythema multiforme may occur.
Other side effects include headaches and dizziness, increase in liver enzymes, oliguria, increase in serum
creatinine, mycosis of the genital tract, fever, shivering and anaphylactic or anaphylactoid reactions.
Nephrotoxic